HyNap-Sora (sorafenib nanoparticle) / Xspray Pharma - LARVOL DELTA

Knowledge structure and dynamic evolution of nanomedicine in liver cancer research: a scientometric analysis and visualization. (PubMed, Front Pharmacol) - "Hepatocellular carcinoma, targeted delivery, sorafenib nanoparticles, and others are current and developing areas of study. In this study, bibliometrics and visual methods were used to review the research of nanomedicine in liver cancer comprehensively. The article will help scholars to gain a better understanding of the dynamic evolution of nanomedicine applications in liver cancer and point the directions for future research."

Journal • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor

Synergistic Action of Benzyl Isothiocyanate and Sorafenib in a Nanoparticle Delivery System for Enhanced Triple-Negative Breast Cancer Treatment. (PubMed, Cancers (Basel)) - "Furthermore, the NPs significantly inhibited cell migration and invasion in TNBC models, surpassing the effects of free drugs. These findings underscore the potential of BITC-SOR-NPs as a promising therapeutic approach for TNBC, offering targeted delivery while minimizing systemic toxicity."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

The effects of metformin and PCL-sorafenib nanoparticle co-treatment on MCF-7 cell culture model of breast cancer. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "In addition, they affected the expression of BCL2 and BAX genes and altered the cell cycle. Together, the combination of PCL-sorafenib/metformin and sorafenib/metformin increased sorafenib absorption at lower doses and also led to apoptosis and oxidative stress increases in MCF-7 cells."

IO biomarker • Journal • Preclinical • Breast Cancer • Oncology • Solid Tumor • ANXA5 • BAX • BCL2 • GPX4 • TP53

Designing an electrochemical sensor based on ZnO nanoparticle-supported molecularly imprinted polymer for ultra-sensitive and selective detection of sorafenib. (PubMed, Anal Chim Acta) - "Also, the imprinting factor (IF) analysis was performed on selected drug substances having structural similarities to SOR and the relative IF values of regorafenib, leflunomide, teriflunomide, nilotinib, axitinib, and dasatinib indicated the selectivity of the developed sensor for SOR...This study is the first electrochemical study for the determination of SOR, and thanks to the ZnO NPs supported MIP sensor, it stands out in terms of both high sensitivity and superior selectivity. Also, this designed sensor provides controlled orientation of the template and complete removal of templates in a one-step process, allowing extremely low detection and quantification limits."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Microfluidics-enabled Serial Assembly of Lipid-siRNA-sorafenib Nanoparticles for Synergetic Hepatocellular Carcinoma Therapy. (PubMed, Adv Mater) - "In vivo, the LSS NPs delivering hypoxia-induced factor (HIF1?)-targeted siRNA efficiently regress tumors of Hep3B xenograft and hepatocellular carcinoma patient-derived primary cells xenograft (PDCX), and finally extend the average survival of PDCX mice to 68 days. Thus, our strategy is promising as a sorafenib/siRNA combination therapy and MESA can be a universal platform for fabricating complex nanosystems."

Journal • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • HIF1A

Cascade two-stage tumor re-oxygenation and immune re-sensitization mediated by self-assembled albumin-sorafenib nanoparticles for enhanced photodynamic immunotherapy. (PubMed, Acta Pharm Sin B) - "(ii) BSA-MHI148@SRF amplified tumor vessel normalization by VEGF inhibition also obviously reversed the tumor immune-suppression microenvironment. Finally, the growth of solid tumors was significantly depressed by such well-designed BSA-MHI148@SRF nanoparticles, which could be potential for clinical cancer therapy."

Journal • Oncology • Solid Tumor

Efficacy of Lipid Nanoparticle-Loaded Sorafenib Combined with Hepatic Artery Chemoembolization in the Treatment of Primary Hepatocellular Carcinoma Complicated with Microvascular Invasion. (PubMed, Dis Markers) - "In addition, the tumor free survival time (TFST), overall survival time (OST), and postoperative 1-year and 2-year survival rates of patients in test group 1 were greatly higher than those in single mode treatment group and control group (P < 0.05). In summary, sorafenib nanoparticles combined with TACE can improve the survival status of patients after resection and delay the time of postoperative tumor recurrence."

Journal • Fibrosis • Gastroenterology • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Immunology • Liver Cirrhosis • Oncology • Solid Tumor

Enhanced oral bioavailability and antitumor therapeutic efficacy of sorafenib administered in core-shell protein nanoparticle. (PubMed, Drug Deliv Transl Res) - "No abnormalities and signs of toxicity were seen in the histopathological analysis for ABSORF-treated animals. In summary, we demonstrate a scalable preparation of small-molecule drug-loaded nanoformulation with approximately two fold enhancement in oral bioavailability, improved antitumor efficacy, and acceptable toxicity profile."

Journal • Gastrointestinal Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor

Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. (PubMed, Theranostics) - "This review provides an overview of hot topics in tumor nanoscience and the latest status of treatments for HCC. It further introduces the current research status of nanoparticle drug delivery systems for treatment of HCC with sorafenib."

Journal • Review • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor

Kulik Addresses Transplant and Therapy in HCC (Targeted Oncology) - "Laura M. Kulik, MD...talked through diagnosing a 77-year-old female patients with hepatocellular carcinoma as well as the treatment options for her disease during a Targeted Oncology Case Based Peer Perspectives event."

Interview